Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.34 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.34 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | TACR3 | P29371 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25288406 | 1.00 | GPR119 (0.34) | GPR119TEAD1TEAD3ALDH1A1KDM4E | |
| SCHEMBL2126084 | 1.00 | GPR119 (0.34) | GPR119TEAD1TEAD3ALDH1A1KDM4E | |
| SCHEMBL1710907 | 0.91 | ALDH1A1 (0.37) | ALDH1A1LMNAAKR1C3ATM | |
| SCHEMBL458216 | 0.91 | GPR119 (0.38) | GPR119TEAD1TEAD3ALDH1A1KDM4E | |
| SCHEMBL21063450 | 0.87 | KDM4E (0.38) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL12503814 | 0.84 | RBP4 (0.36) | GPR119ALDH1A1LMNATSHRL3MBTL1 | |
| SCHEMBL3717160 | 0.84 | RBP4 (0.36) | GPR119ALDH1A1LMNATSHRL3MBTL1 | |
| SCHEMBL18641574 | 0.84 | RBP4 (0.36) | GPR119ALDH1A1LMNATSHRL3MBTL1 | |
| SCHEMBL345454 | 0.82 | GPR119 (0.51) | GPR119SCN9A | |
| SCHEMBL3124615 | 0.82 | GPR119 (0.51) | GPR119SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295126-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | TARGACEPT, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11542253-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | Oyster Point Pharma, Inc. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210371401-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | OYSTER POINT PHARMA INC. | 2021-12-02 | — | — | US | disclosed |
| US-10919879-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | Oyster Point Pharma, Inc. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200207740-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | OYSTER POINT PHARMA INC. | 2020-07-02 | — | — | US | disclosed |
| EP-3279195-B1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | OYSTER POINT PHARMA INC (US) | 2020-07-01 | — | — | EP | disclosed |
| US-10421745-B2 | Salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | Oyster Point Pharma, Inc. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190071428-A1 | NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | OYSTER POINT PHARMA INC. | 2019-03-07 | — | — | US | disclosed |
| US-9981949-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | Oyster Point Pharma, Inc. (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3279195-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE | Oyster Point Pharma, Inc. (US) | 2018-02-07 | — | — | EP | disclosed |
| EP-2544690-A2 | ARYLVINYLAZACYCLOALKANE COMPOUNDS FOR CONSTIPATION | Targacept Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| EP-2358670-B1 | A process for the preparation of tert-butyl (R)-3-vinylpyrrolidine-1-carboxylate and intermediates therefor | TARGACEPT INC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120157477-A1 | REVERSAL OF L-DOPA-INDUCED DYSKINESIA BY NEURONAL NICOTINIC RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| EP-2442810-A2 | REVERSAL OF L-DOPA-INDUCED DYSKINESIA BY NEURONAL NICOTINIC RECEPTOR LIGANDS | Targacept Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2358670-A2 | Novel compounds | Targacept Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| EP-2358705-A1 | (R) -3- (E) -2- (PYRR0LIDIN-3-YL) VINYL) -5- (TETRAHYDR0PYRAN-4-YL0XY) PYRIDINE, ITS SALTS, ITS SYNTHESIS AND ITS USE AS LIGAND FOR NICOTINIC ACETYLCHOLINERGIC RECEPTORS | Targacept Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010147938-A2 | REVERSAL OF L-DOPA-INDUCED DYSKINESIA BY NEURONAL NICOTINIC RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010065449-A1 | (R) -3- (E) -2- (PYRR0LIDIN-3-YL) VINYL) -5- (TETRAHYDR0PYRAN-4-YL0XY) PYRIDINE, ITS SALTS, ITS SYNTHESIS AND ITS USE AS LIGAND FOR NICOTINIC ACETYLCHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065443-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065447-A2 | NOVEL COMPOUNDS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157477-A1 | REVERSAL OF L-DOPA-INDUCED DYSKINESIA BY NEURONAL NICOTINIC RECEPTOR LIGANDS | CHRNA5, CHRNA2, CHRNA3 | GPR119 198/4885TEAD1 4109/4885TEAD3 3335/4885 |
| US-20210371401-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | DPYD, DHPS, NUDT5 | GPR119 4309/4885TEAD1 4190/4885TEAD3 3168/4885 |
| US-10919879-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | DPYD, DHPS, NUDT5 | GPR119 4309/4885TEAD1 4190/4885TEAD3 3168/4885 |
| US-20200207740-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | DPYD, DHPS, NUDT5 | GPR119 4309/4885TEAD1 4190/4885TEAD3 3168/4885 |
| US-20230295126-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | DPYD, DHPS, NUDT5 | GPR119 4309/4885TEAD1 4190/4885TEAD3 3168/4885 |
| US-20190071428-A1 | NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | DPYD, SLC6A7, SLC6A5 | GPR119 4379/4885TEAD1 4435/4885TEAD3 3172/4885 |
| US-10421745-B2 | Salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | DPYD, SLC6A7, NUDT5 | GPR119 4274/4885TEAD1 4380/4885TEAD3 3055/4885 |
| US-11542253-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | DPYD, DHPS, NUDT5 | GPR119 4309/4885TEAD1 4190/4885TEAD3 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.